Assay Readouts: TCID50, qPCR, and Plaque—What to Use


Assay Readouts: TCID50, qPCR, and Plaque—What to Use

Published on 29/11/2025

Assay Readouts: TCID50, qPCR, and Plaque—What to Use

This comprehensive guide will provide a step-by-step analysis of the assay readouts TCID50, qPCR, and Plaque assays, emphasizing their respective roles in viral clearance validation in the context of spiking studies. The focus will also include the considerations necessary for closed systems and single-use systems, aligned with cGMP and regulatory frameworks established by the US FDA, EMA, MHRA, and PIC/S.

Understanding Viral Clearance Validation

Viral clearance validation is a critical process in the development of biologics and advanced therapy medicinal products (ATMPs). This validation ensures that any potential viral contaminants are effectively removed or inactivated during the manufacturing process, thereby safeguarding patient safety. As regulatory bodies such as the FDA and EMA establish rigorous guidelines, it becomes essential for pharmaceutical professionals to understand the methodologies employed, especially during spiking studies.

Spiking studies simulate the worst-case scenarios where viral contaminants are introduced into the production process to assess the efficacy of the viral clearance methods employed. In this context, understanding how to accurately measure viral loads through various assay readouts is imperative. Choosing the right assay for this purpose involves evaluating the type of viral challenge, the nature of the product, and the specific control measures in place.

Common Assay Readouts in Viral Clearance

Within the realm of viral clearance validation, three primary assay methods are frequently employed: TCID50, qPCR, and plaque assays. Each of these methodologies serves a distinct purpose and has its own merits and limitations which need to be understood when undertaking validation strategies.

1. TCID50 (Tissue Culture Infectious Dose 50)

TCID50 is widely used for determining the infectivity of viruses in a given sample. This assay measures the dilution of a viral sample that causes cytopathic effects in 50% of the inoculated cell cultures, providing a quantitative measure of viral load.

  • Pros: Provides a precise measurement of viral infectivity and is adaptable to many viral types.
  • Cons: Time-consuming and requires specialized cell culture resources.

When conducting spiking studies using TCID50, the cell line selection, incubation times, and the type of viral target are crucial. Careful consideration must be given to these factors to ensure that the results are reproducible and in alignment with regulatory expectations.

2. qPCR (Quantitative Polymerase Chain Reaction)

qPCR is a molecular technique utilized to amplify and quantify targeted DNA sequences. In the context of viral clearance validation, it is predominantly used for assessing viral genetic material, providing rapid insights into viral loads.

  • Pros: Highly sensitive and specific, capable of detecting low viral loads within a sample.
  • Cons: Only quantifies genetic material and doesn’t account for the infectivity of the virus.

The implementation of qPCR in spiking studies complements TCID50 assays by allowing quantification of viral genetic material alongside assessments of infectious doses. This dual approach enhances the robustness of validation methodologies.

3. Plaque Assay

Plaque assays provide a visual representation of viral infectivity by measuring the number of viral plaques formed in a monolayer of cells following viral infection. Each plaque corresponds to a single viral infection event, providing a direct count of viable viruses.

  • Pros: Directly measures infectivity and is considered the gold standard for certain viral types.
  • Cons: Labor-intensive and requires appropriate cell cultures and incubation facilities.

The plaque assay can be particularly useful in spiking studies where infectivity and viral load need to be analyzed simultaneously. Understanding the kinetics of plaque formation can guide modifications in the production process to enhance viral clearance.

Choosing the Right Assay for Spiking Studies

Choosing the most suitable assay for viral clearance validation is not a one-size-fits-all decision. It requires thorough consideration of multiple factors, including the type of viral load, intended product, and specific regulatory requirements outlined in ICH Q5A(R2).

Factors Influencing Assay Selection

  • Type of Viral Contaminant: Depending on whether you are dealing with enveloped or non-enveloped viruses, the specific assay may vary in appropriateness.
  • Viral Load Expectations: The anticipated level of viral contamination will influence whether you choose a more sensitive assay like qPCR or a traditional assay like TCID50.
  • Regulatory Considerations: Compliance with guidelines such as those from the EMA and PIC/S will dictate the level of rigor expected in assay validation.

Using a combination of the assays may provide a more comprehensive understanding of the viral clearance process. It is important to design studies in accordance with aseptic controls set out in Annex 1 to ensure product integrity and safety.

Addressing Viral Clearance in Closed and Single-Use Systems

As the biopharmaceutical industry shifts towards closed systems and single-use systems, it is crucial to adapt viral clearance strategies accordingly. These systems offer significant advantages in minimizing contamination risks and simplifying manufacturing processes. However, they also pose unique challenges in viral clearance validation.

Advantages of Closed and Single-Use Systems

  • Reduced Risk of Contamination: By maintaining closed processes, the potential for environmental contaminations is significantly decreased.
  • Operational Efficiency: Single-use systems facilitate easier workflows while minimizing the need for extensive cleaning and sterilization.

Validation Considerations for Closed Systems

When validating viral clearance in closed or single-use systems, the following key considerations should be incorporated:

  • Chain of Identity Custody: Maintain a thorough record of all materials used throughout the process to ensure traceability.
  • Process Characterization: Understand how the materials interact within a closed system to assess their viral clearance capabilities properly.
  • Variability in Responses: Recognize that the behavior of viral contaminants may differ in closed systems compared to traditional open environments.

Regular assessments must be conducted to ensure compliance with industry standards and efficacy in viral clearance operations, ultimately supporting more robust manufacturing efficiencies.

Implementing Process Performance Qualification (PPQ) and Continued Process Verification (CPV)

Implementing an effective PPQ and CPV strategy is crucial for maintaining compliant and efficient manufacturing processes for biologics and ATMPs. This involves tailoring parameters to align with specific product characteristics and the type of viral clearance strategy employed.

PPQ Tailoring for ATMP

PPQ for ATMPs should be tailored to reflect the unique challenges associated with these therapies, especially regarding product variability and complexities involved in cellular components and their viral clearance:

  • Establishing Acceptance Criteria: Define clear acceptance criteria in alignment with relevant CQAs, including potency and identity.
  • Process Consistency: Ensure that the validation protocols encompass all aspects of the production process, including raw material variability.

Continuous Process Verification (CPV)

CPV is an essential ongoing process for monitoring and improving manufacturing consistency. It allows for real-time assessment of process data against established control limits:

  • Real-Time Data Analysis: Incorporate data analytics to identify trends in process performance, directly impacting viral clearance effectiveness.
  • Feedback Loops: Establish mechanisms to adjust the manufacturing process in response to CPV results, helping to maintain product quality and safety.

In light of guidelines from the WHO and other international standards, the synergy between PPQ and CPV ensures that facilities remain compliant while improving their viral clearance strategies over time.

Conclusion

In conclusion, selecting the appropriate assay readout for viral clearance validation is fundamental when conducting spiking studies in biologics and ATMP manufacturing. Understanding the strengths and weaknesses of TCID50, qPCR, and plaque assays equips pharmaceutical professionals to make informed decisions relevant to their specific product and operational context. Additionally, as the industry moves towards closed and single-use systems, maintaining compliance with regulatory guidelines and establishing robust PPQ and CPV frameworks becomes increasingly crucial for ensuring product safety and efficacy. By integrating these elements, professionals can effectively navigate the complexities of viral clearance validation and contribute to the safe delivery of biopharmaceuticals to patients globally.